entinostat has been researched along with Osteogenic Sarcoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kiany, S | 1 |
| Harrison, D | 1 |
| Gordon, N | 1 |
| Rao-Bindal, K | 3 |
| Koshkina, NV | 2 |
| Stewart, J | 1 |
| Kleinerman, ES | 4 |
| Huang, G | 1 |
| Nishimoto, K | 1 |
| Yang, Y | 1 |
| Zhou, Z | 1 |
2 reviews available for entinostat and Osteogenic Sarcoma
| Article | Year |
|---|---|
The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma.
Topics: Benzamides; Bone Neoplasms; Fas Ligand Protein; Gene Expression Regulation, Neoplastic; Histone Deac | 2020 |
Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases.
Topics: Animals; Antineoplastic Agents; Benzamides; Bone Neoplasms; Deoxycytidine; Epigenesis, Genetic; Fas | 2014 |
3 other studies available for entinostat and Osteogenic Sarcoma
| Article | Year |
|---|---|
The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Bone Neoplasms; CASP8 and | 2013 |
Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.
Topics: Administration, Inhalation; Animals; Base Sequence; Benzamides; Blotting, Western; Cell Line, Tumor; | 2011 |
MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts.
Topics: Apoptosis; Benzamides; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Fas Ligan | 2012 |